logo

Neurobo Pharmaceuticals, Inc. (NRBO)



Trade NRBO now with
  Date
  Headline
8/10/2018 6:03:17 AM Gemphire Therapeutics Unveils Termination Of Phase 2a Trial Of Gemcabene In Pediatric NAFLD
5/3/2018 4:45:23 PM Gemphire Therapeutics Appoints Steven Gullans As Its President And CEO
2/8/2018 9:01:02 AM Gemphire Announces Pricing Of $22 Mln Public Offering Of Common Stock
1/17/2018 6:30:39 AM Gemphire Completes Patient Enrollment In INDIGO-1 Trial In Severe Hypertriglyceridemia Patients
9/15/2016 6:20:51 AM RBC Capital Markets Is Cutting Gemphire Therapeutics Inc. (GEMP) 2018 Estimate To -2.19 From -2.01
9/15/2016 6:20:35 AM RBC Capital Markets Is Lowering Gemphire Therapeutics Inc. (GEMP) 2017 Estimate To -1.99 From -1.83
9/15/2016 6:20:20 AM RBC Capital Markets Is Increasing Gemphire Therapeutics Inc. (GEMP) 2016 Estimate To -1.97 From -2.24
9/15/2016 6:20:01 AM RBC Capital Markets Is Lowering Gemphire Therapeutics Inc. (GEMP) Q4 17 Estimate To -0.51 From -0.33
9/15/2016 6:19:43 AM RBC Capital Markets Is Cutting Gemphire Therapeutics Inc. (GEMP) Q3 17 Estimate To -0.39 From -0.34
9/15/2016 6:19:26 AM RBC Capital Markets Is Lowering Gemphire Therapeutics Inc. (GEMP) Q2 17 Estimate To -0.64 From -0.59
9/15/2016 6:19:11 AM RBC Capital Markets Is Raising Gemphire Therapeutics Inc. (GEMP) Q1 17 Estimate To -0.52 From -0.56